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Abstract
Background
The majority of chordomas show activation of the platelet-derived growth factor receptor
(PDGFR). Based on in vitro intertumoral variation in response to recombinant PDGF protein
and PDGFR inhibition, and variable tumor response to imatinib, we hypothesized that chor-
domas resistant to PDGFR inhibition may possess downstream activation of the pathway.
Methods
Molecular profiling was performed on 23 consecutive chordoma primary tissue specimens.
Primary cultures established from 20 of the 23 specimens, and chordoma cell lines, UCH-1
and UCH-2, were used for in vitro experiments.
Results
Loss of heterozygosity (LOH) at the phosphatase and tensin homolog (PTEN) locus was
observed in 6 specimens (26%). PTEN disruption statistically correlated with increased Ki-
67 proliferation index, an established marker of poor outcome for chordoma. Compared to
wild type, PTEN deficient chordomas displayed increased proliferative rate, and responded
less favorably to PDGFR inhibition. PTEN gene restoration abrogated this growth advan-
tage. Chordomas are characterized by intratumoral hypoxia and local invasion, and histone
deacetylase (HDAC) inhibitors are capable of attenuating both hypoxic signaling and cell
migration. The combination of PDGFR and HDAC inhibition effectively disrupted growth
and invasion of PTEN deficient chordoma cells.
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Conclusions
Loss of heterozygosity of the PTEN gene seen in a subset of chordomas is associated with
aggressive in vitro behavior and strongly correlates with increased Ki-67 proliferative index.
Combined inhibition of PDGFR and HDAC attenuates proliferation and invasion in chor-
doma cells deficient for PTEN.
Introduction
Chordoma is a primary bone cancer believed to arise from the remnants of the notochord, a
developmental structure located along the midline that defines the primitive axis of the embryo
[1–3]. Consistent with its origin, chordomas are largely restricted to opposing ends of the axial
skeleton with the majority found at the sacrum and skull base. Histologically they are charac-
terized by a vacuolated or “physaliphorous,” morphology [4, 5]. Chordomas are slow-growing,
low-grade bone cancers characterized by frequent local recurrence. Standard therapy consists
of surgical resection, but due to the critical location of the tumor and its invasiveness, complete
resection is frequently infeasible. Local control presents a major clinical challenge in the man-
agement of chordomas and recurrence eventually leads to the patient’s demise. The median
survival after diagnosis is 6–7 years, with 5- and 10-year survival rates of 68% and 40%, respec-
tively [1, 3]. Adjuvant therapy consists of radiation therapy, primarily stereotactic delivery of
gamma radiation or proton beam radiotherapy [3, 6, 7]. These delivery methods are preferred
due to the high doses required to achieve tumor control, the radiosensitive nature of the adja-
cent structures, and favorable dose fall off compared to conventional radiotherapy. However,
the poor overall prognosis makes the development of effective adjuvant treatment regimens
critical to improving patient survival.
Although chordomas are considered to be relatively resistant to chemotherapy, there are
case reports of occasional response [8–10]. The only prospectively evaluated pharmacothera-
peutic approaches consist of three phase II clinical trials. A topoisomerase I inhibitor, 9-nitro-
camptothecin, was investigated in 15 patients and appeared to delay progression of disease
[11]. Following the immunohistochemical demonstration that PDGFR is activated in a major-
ity of chordomas, patients with chordoma were treated with imatinib mesylate, a tyrosine
kinase inhibitor active against PDGFR, BCR-ABL, and KIT [12, 13]. All participating subjects’
tumor showed phosphorylation of the PDGFR. The investigators noted 1 partial response and
35 subjects with stable disease from a total of 50. More recently, lapatinib was investigated in
subjects with advanced EGFR-positive chordoma. Six subjects representing 33% of total dem-
onstrated partial response [14]. These experiences show the potential role of chemotherapy in
improving outcome for patients with chordoma, although identification of more effective strat-
egies is needed.
We have previously observed that PDGF is both mitogenic and motogenic for chordoma
cells cultured from acutely resected surgical specimens [15]. Based on our observation of in
vitro intertumoral variation in response to recombinant PDGF protein and PDGFR inhibition
and the results of the imatinib clinical trial, we hypothesized that chordomas resistant to
PDGFR inhibition may possess downstream activation of the pathway.
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Materials and Methods
Patients and tumor tissues
The University of Pittsburgh Institutional Review Board approved the study, "Prospective and
Retrospective Analysis of Chordoma Tissues and Records for Determination of Growth and
Invasive Mechanisms.”Written informed consents were obtained from all subjects prior to sur-
gery. For minors, written consents were obtained from parents/guardians. The process was doc-
umented by the investigator and research coordinator. The IRB approved the consenting
procedure. All tissues included in the study were clinically confirmed to be chordomas by a
pathologist. Tumor specimens were collected prospectively after obtaining informed consent
from 23 subjects with chordoma. Resected tumor tissue was immediately placed into sterile
DMEM-F12 (GIBCO-Invitrogen, La Jolla, CA) tissue culture medium on ice and transported to
the laboratory. Tumors were minced with a scalpel and mechanically dissociated by trituration.
Cell culture
Chordoma cells were cultured in DMEM/F12 medium supplemented with 2 mM glutamine, 1
mM sodium pyruvate, 100 U/ml penicillin, 100 μg/ml streptomycin (Gibco BRL, Gaithersburg,
MD), and 10% heat inactivated fetal bovine serum (Gibco BRL) in a humidified incubator at 37
degrees C. Chordoma cells were identified by the characteristic physaliphorous morphology
and expression of brachyury by immunohistochemistry and immunoblot. Cells were passaged
upon achieving confluence and used up to 10 passages as long as they retained the physaliphor-
ous morphology.
Chordoma cell lines UCH-1 and UCH-2 were obtained from the Chordoma Foundation.
UCH-1 and UCH-2 cells were grown on plates coated with 0.005% collagen (Sigma) in a 4:1
mixture of Iscove’s modified Dulbecco’s medium (Invitrogen) and RPMI-1640 (Sigma) media
containing 10% fetal bovine serum, 1 mM L-glutamine, and 26 mM sodium bicarbonate in a
37°C humidified tri-gas incubator. Human glioma lines U87MG and T98G were purchased
from American Tissue Type Culture Collection (Manassas, VA, USA) and cultured as previ-
ously described [16].
Hypoxic condition
Cells were incubated in a hypoxic chamber (Forma Scientific, Marietta, OH) with a 93:5:2 mix-
ture of N2/CO2/O2. Deoxygenated media were prepared prior to each experiment by equilibrat-
ing with a hypoxic gas mixture containing 93% N2, 5% CO2, and 2% O2 at 37 degrees C.
Antibodies and inhibitors
Anti-phospho-PI3K, anti-PI3K, anti-laminB antibody, anti-phospho-PDGF-αT720, anti-
PDGF-α, anti-phospho-PDGF-βT1009, and anti-PDGF-β antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-HIF-1α antibody was purchased from
BD Biosciences (San Jose, CA, USA). Anti-PTEN, anti-phospho-mTorS2448, anti-mTOR, anti-
phospho-AktS473, anti-phospho-AktT308, anti-Akt, anti-phospho-ERK1/2T202/T204, and anti-
ERK1/2 antibodies were purchased from Cell Signaling (Beverly, MA, USA). Anti-brachyury
antibody was purchased from R&D Systems. Anti-mouse-IgG-HRP and anti-rabbit-IgG-HRP
secondary antibodies were purchased from Santa Cruz Biotechnology. The PDGFR inhibitor,
3-Fluoro-N-(6,7-dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine, was obtained
from EMD Chemicals (Gibbstown, NJ, USA, catalog #521233). A concentration of 1 μMwas
used for these studies. LBH589 was obtained from Selleck (Houston, TX, USA, catalog
#S1030).
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Enzyme-linked immunosorbent assay (ELISA) for detection of vascular
endothelial growth factor (VEGF)
Levels of VEGF protein in the media were determined by ELISA using a commercial kit (R&D
Systems, Minneapolis, MN, USA) as previously described [16].
Immunoblot and immunohistochemistry
These were performed as previously described [17]-[18]. Briefly, immunoblot analyses were per-
formed by cell lysis in a buffer consisting of 20 mMTris-HCl (pH 7.4, 150 mMNaCl, 1mM
EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerol phosphate, 1mM
Na3VO4, 1 μM/ml leupeptin and 1mM phenylmethylsulfonyl fluoride). After sonication, lysates
were clarified by centrifugation at 12,000 x g for 10 minutes at 4°C, and protein content in the
supernatant was measured according to the Bradford method. Aliquots (30–50 μg of protein per
lane) of total protein were separated by 7.5–15% SDS-polyacrylamide gel electrophoresis and
blotted onto nitrocellulose transfer membrane. Each membrane was blocked with 5% non-fat
dry milk in TBS-T for 1 hour at room temperature, followed by incubation with the appropriate
primary antibodies overnight at 4°C. After extensive washing with TBS-T, each membrane was
incubated with horseradish peroxidase-conjugated secondary antibodies at 1:1000 dilution for 1
hour at room temperature in TBS-T. Detection was performed using chemiluminescence
reagent. Immunohistochemistry on paraffin-embedded chordoma tumor specimen was per-
formed using antibody against brachyury (R&D Systems). 5 μm sections were deparaffinized and
underwent heat-induced epitope retrieval. Slides were then incubated with primary antibody and
detected using avidin-biotin-peroxidase complex with 3,3’-diaminobenzidine as the chromogen.
Brachyury expression analyses
Brachyury was detected using both immunoblot and immunohistochemistry. Nuclear expres-
sion was confirmed by immunohistochemistry and by immunoblot performed on isolated
nuclear protein fraction.
Nuclear extraction
We isolated nuclear proteins using a commercially available kit (Pierce Protein Biology Prod-
ucts, Rockford, IL) following the manufacturer’s instructions.
PCR-based microsatellite LOH analysis
Manual microdissection of the tissue sample was performed and specimens with a minimum
of 50% of tumor cells in a microdissection target were accepted for analysis. DNA was isolated
using standard laboratory procedures. Optical density readings were obtained. The assay uti-
lized 2 microsatellite markers on chromosome 10q23 near the PTEN locus (D10S520,
D10S1173). PCR was performed and the PCR products were analyzed using capillary gel elec-
trophoresis on GeneScan ABI 3730 (Foster City, CA). Relative fluorescence was determined for
individual alleles and the ratio of peaks was calculated. Neoplastic tissue was then analyzed to
detect loss of heterozygosity. As normal tissue was usually not available, peak height ratios fall-
ing outside of 2 standard deviations beyond the mean for each polymorphic allele paring were
assessed as showing loss of heterozygosity.
Invasion assay
The BD BioCoat Matrigel Invasion Chamber assay system was used to study the effects of
inhibitors on chordoma cell invasion (BD Biosciences, MA). Briefly, precoated filters (8 μm
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pore-size, Matrigel 100 μg/cm2) were rehydrated and seeded with 2.5 x 104 cells in 500 μl of
medium with or without inhibitors in triplicates into the upper part of each chamber. The
lower compartment was filled with 750 μl of serum-free DMEM/F-12 supplemented with 0.1%
BSA. After incubation for 18 h at 37 degrees C, non-invaded cells on the upper surface of the
filter were wiped with a cotton swab, and migrated cells on the lower surface of the filter were
fixed and stained with Diff-Quick kit. Invasiveness was determined by counting cells in five
microscopic fields per well, and the extent of invasion was expressed as an average number of
cells per microscopic field.
Cell proliferation assay
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) assay was used according to the manufacturer’s recommendations (Promega, Madison,
WI). UCH-1 and C-18 chordoma cells were infected with PTEN-encoding adenoviruses (Ad-
PTEN) or control adenoviruses (Ad-con) at an MOI (multiplicity of infection) = 10. After 24 h,
the cells were treated with the PDGFR inhibitor or DMSO control. The cells were subsequently
collected every day for five days and counted with a hemocytometer.
Annexin V-PE and 7-AAD flow cytometry
The effects of PTEN expression on PDGFR inhibitor-mediated effects on apoptosis were
assessed by Annexin V-PE and 7-AAD flow cytometry. UCH-1 and C18 cells were infected
with Ad-PTEN or Ad-con for 24 h and then were treated with PDGFR inhibitor for 48 h. Cells
were harvested and stained with Annexin V-PE and 7AAD according to the manufacturer's
instructions. Cell samples were analyzed on a FACsan flow cytometer and apoptotic fractions
were determined.
Vectors and Transfections
Adenoviruses encoding wild-type PTEN (Ad-PTEN) and control adenovirus (Ad-control)
were constructed as described previously [19, 20]. Cells were infected with adenovirus vectors
(MOI = 10) for 24 h before treatment with PDGFR inhibitor.
Statistical analysis
Statistical analysis was carried out using Graphpad InStat 3 software (GraphPad Software, Inc.,
San Diego, CA, USA). Results were considered statistically significant at p< 0.05.
Results
Patient characteristics
Chordoma tissues from 23 patients were analyzed (Table 1). There were 18 men and 5 women.
Ages ranged from 6 to 77 years. Seventeen were cases at first presentation and 6 were recurrent
tumors. All specimens showed nuclear expression of brachyury by immunohistochemistry. We
show one representative immunohistochemical staining and four immunoblots with control
cancer cell lines that do not express brachyury (S1 Fig). Immunoblot performed on isolated
nuclear protein fraction indicates nuclear localization of brachyury (S6 Fig).
Loss of PTEN
PCR-based microsatellite LOH analysis of the 10q23 locus revealed LOH at 10q23, indicating
loss of PTEN gene in 6 of 23 specimens (S2 Fig). In agreement, immunoblot of the primary
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culture cells established from the chordoma tissues with LOH at 10q23 showed decreased or
absent PTEN expression (Fig 1). Chordoma tissues without LOH at 10q23 demonstrated
PTEN protein expression (Fig 1). Previously characterized cell lines served as positive and neg-
ative controls (Fig 1).
Chordoma cells deficient for PTEN show increased in vitro growth and
resistance to PDGFR inhibition
To characterize the role of PTEN on growth of chordoma cells, primary cultures were estab-
lished from 20 of 23 tumor specimens. Ten specimens (all PTEN wild type) showed very slow
growth rates, limiting experimental use. Therefore, primary cultures were established from 14
PTEN wild type and 6 PTEN deficient tumor specimens. From the remaining 4 PTEN wild
type chordomas, three demonstrated particularly robust in vitro growth. These PTEN wild
type tumors were used to compare growth rate and invasiveness to the PTEN deficient chor-
doma tumor cells. Chordoma cells lacking PTEN expression demonstrated accelerated in vitro
growth rate with shorter doubling time compared to PTEN wild type chordomas as determined
by cell number and by MTS proliferation assay (Fig 1). To determine the effect of PTEN status
on chordoma cellular response to PDGFR inhibition, chordoma cells from PTEN deficient and
wild type tumors were exposed to a PDGF receptor tyrosine kinase inhibitor. We investigated
the effect of PDGFR inhibition on proliferative rate and invasive capacity. We did not detect a
Table 1. Patient and tumor characteristics from 23 consecutive surgically resected chordomas.
Case Sex Age (Years) Site Type 10q LOH Ki-67 (%)
1 M 22 Clivus Primary No 2
2 M 35 Clivus Primary No 1.5
3 M 61 Clivus Primary No 4
4 M 70 Clivus Primary No 0.5
5 M 63 Clivus Primary Yes 4
6 M 32 Clivus Recurrent No 2.5
7 F 77 Cervical Primary No 15
8 M 30 Clivus Primary No 2.5
9 F 37 Clivus Recurrent No 0.5
10 M 20 Clivus Primary No 1.5
11 F 72 Clivus Primary No 5
12 F 46 Clivus Recurrent No 2.5
13 M 28 Clivus Primary Yes 20
14 M 41 Clivus Primary Yes 10
15 M 52 Clivus Primary No 5
16 M 26 Clivus Primary Yes 3
17 M 66 Clivus Recurrent No 5
18 M 6 Clivus Recurrent Yes 12.5
19 M 60 Clivus Primary No 0.5
20 M 43 Clivus Primary No 1
21 M 73 Clivus Primary Yes 10
22 F 24 Clivus Primary No 0.5
23 M 56 Clivus Recurrent No 12.5
Abbreviations: LOH, Loss of heterozygosity.
doi:10.1371/journal.pone.0134426.t001
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significant difference in proliferative rate in response to the PDGFR inhibitor (Fig 1). Also, the
in vitro invasive capacity of PTEN wild type and PTEN deficient tumors were similar (Fig 1).
However, PTEN deficient tumors showed greater resistance to PDGFR inhibition on invasion
compared to PTEN wild type cells (Fig 1).
Fig 1. PTEN disruption in Chordoma is associated with enhanced in vitro proliferation and invasion. (A) A representative immunoblot for PTEN
expression demonstrating a decreased level of expression of PTEN in the chordoma specimens with LOH at 10q23 locus compared with wild type
chordomas. T98G is used as a positive control and U87MG is used as a negative control for PTEN expression. This is a representative blot from three
independent experiments. (B)Cell proliferation assay assessed by the MTSmethod demonstrating a higher rate of proliferation among chordoma cell lines
with PTEN LOH compared with wild type. ** P<0.05, Two sample independent student’s t test. (C and D) Cell proliferation assay assessed by MTSmethod
demonstrating a higher rate of proliferation for chordoma lines with PTEN LOH compared with wild type. Addition of 50ng/mL of PDGF results in increased
proliferation in both PTEN LOH and wild type cells. Addition of 1 uM of PDGF inhibitor resulted in decreased proliferation compared to untreated control.
**P<0.05, Two sample independent student’s t test compared to untreated control from respective cell lines. (E) A representative matrigel invasion assay
from demonstrating significant decrease in invasion in response to PDGF inhibition among PTENwild type chordoma lines compared with PTEN +/- cells.
These images are representative of 3 independent experiments. *P<0.05, Two sample independent student’s t test.
doi:10.1371/journal.pone.0134426.g001
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PTEN restoration results in attenuation of growth
To confirm that PTEN deficiency drives chordoma proliferation and resistance to PDGFR
inhibition and is not merely a bystander, we restored PTEN expression in two chordoma cell
lines lacking PTEN. Lines C18, C21 (primary culture) and UCH-1 (established chordoma cell
line) showed attenuation of proliferative rate (Fig 2 and S5 Fig). Increase in apoptosis and
attenuation of invasive capacity was only seen in the primary culture C18 and not with UCH-1,
an established cell line (Fig 3). However, PTEN restoration established sensitivity to PDGR
inhibition in both cell lines (Fig 3 and S2 Fig).
HDAC inhibition attenuates expression of the hypoxia inducible factor 1
alpha (HIF-1α) and results in decreased chordoma cell proliferation and
invasion
Chordomas harbor regions of intratumoral hypoxia that can contribute to treatment resis-
tance.[21, 22] To identify potential therapeutics effective in low oxygen setting, we character-
ized in vitro propagation of chordoma cells at 2% oxygen and observed increased proliferative
rate (Fig 4) and level of vascular endothelial growth factor (VEGF), a transcriptional target of
HIF-1α (Fig 4). Treatment with HDAC inhibitor LBH589 (25 nM) led to reduction of HIF-1α
level (Fig 4).
Combined PDGFR and HDAC inhibition is associated with reduction in
invasion and proliferation
Chordoma cells with intact PTEN expression and those deficient for PTEN both demonstrate
greater potential therapeutic response to the combination of PDGFR inhibitor and HDAC
inhibition (Fig 5). The benefit of combined inhibition was particularly significant for attenua-
tion of invasion (Fig 5).
Discussion
Identifying the determinants of tumor resistance to therapy is important for improving patient
care and will likely lead to better understanding of the underlying biology [23]. In this study,
we profiled 23 chordoma specimens, and investigated mechanisms of in vitro proliferation and
invasion of chordoma cells to identify effective combinatorial regimens. Because availability of
established chordoma cell lines is limited, we relied on primary culture specimens. We found
that primary culture of chordoma can be established, and PTEN is lost in a subset of chordoma
[24]. This loss leads to enhanced in vitro growth and relative resistance to PDGFR inhibition
compared to chordomas with intact PTEN expression. Interestingly, we observed that PTEN
loss was associated with greater resistance to proliferation compared to invasion. Such observa-
tion may in part explain paucity of tumor shrinkage, but high number of subjects with stable
disease with the use of single agent imatinib for chordoma [13]. Determining the functional
significance of PTEN loss in chordoma and the observation that such loss may result in resis-
tance to upstream inhibition may provide design of therapeutic strategies to overcome such
disruptions.
This study was performed because: 1) experience from a clinical trial demonstrated variable
clinical response of chordomas to PDGFR inhibition despite all tumors showing activation of
PDGFR; and 2) our in vitro laboratory observation of intertumoral variation in growth rate
and response to PDGR inhibition of chordoma cells. To identify the potential molecular basis
for such observations, we profiled chordoma specimens and investigated the in vitro growth
characteristics. All histologically confirmed chordoma specimens demonstrated nuclear
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expression of brachyury. Because brachyury expression becomes restricted to the notochord
during development, this marker is useful in distinguishing chordomas from other tumors
[25–27].
Addition of recombinant PDGF to the chordoma cells led to downstream activation of
appropriate signaling pathways (S3 Fig). We observed LOH at 10q23, a locus that contains the
PTEN gene, in a subset of chordomas. LOH at 10q23 was statistically significant for increased
Ki-67, an established negative prognostic indicator for chordoma (S4 Fig). PTEN gene encodes a
phosphatidylinositol-3,4,5-triphosphate (PIP3) phosphatase that functions as an important neg-
ative regulator of the PI3K-Akt signaling pathway. Considering that the PI3K-Akt network
activity is amplified in many human cancers, it is not a surprise that PTEN is one of the most
commonly disrupted tumor suppressors in cancers [28]. Investigations into the pattern of
PTEN loss in cancers show that LOH is a significantly more common finding than biallelic gene
inactivation [29]. Subsequent studies showed that the loss of heterozygosity at the PTEN locus is
important in tumorigenesis because PTEN is a haploinsufficient tumor suppressor [29–31].
Fig 2. Restoration of PTEN expression attenuates in vitro proliferation of Chordoma cells. (A) A representative immunoblot demonstrating
reconstitution of PTEN expression via adenoviral delivery. (B) A representative immunoblot for phospho-PDGFRb demonstrating decreased expression with
administration of PDGFR inhibitor compared with vehicle controls. (C and D) Cell proliferation assays assessed by the MTSmethod for C18 cell line (PTEN
+/-) and UCH1 cell line (PTEN +/-), respectively, demonstrating decreased proliferation with restoration of PTEN and administration of PDGFR inhibitor.
*P<0.05, Two sample independent student’s t test compared with untreated control. **P<0.05, Two sample independent student’s t test compared with
PDGFR inhibitor group.
doi:10.1371/journal.pone.0134426.g002
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Fig 3. PTEN reconstitution enhances Chordoma cell sensitivity PDGFR inhibition . (A and B) Representative apoptosis assays for (A) C18 cell line
(PTEN +/-) and (B) UCH1 cell line (PTEN +/-), respectively, assessed by Annexin-V and 7-AAD florescence demonstrating significantly higher rates of
apoptosis with restoration of PTEN and administration of PDGFR inhibitor compared with control. *P<0.05, Two sample independent student’s t test. This is
representative of three independent experiments. (C and D) Representative matrigel invasion assays with the C18 cell line (PTEN +/-) and UCH1 cell line
(PTEN +/-), respectively, demonstrating significant decrease in invasion in response to PDGF inhibition with restoration of PTEN expression. These images
are representative of 3 independent experiments. *P<0.05, Two sample independent student’s t test.
doi:10.1371/journal.pone.0134426.g003
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In half of the chordoma cases with LOH at 10q23, we observed absence of PTEN protein
expression. There are several possible explanations for loss of PTEN protein with deletion of
one allele. Mutation of the PTEN promoter on the retained allele can result in gene silencing
[32]. Also epigenetic mechanisms, specifically methylation of the promoter have been
described [33–36].
It has been previously demonstrated that PTEN deficient cells exhibit increased prolifera-
tion, reduced apoptosis, and enhanced migration [37–39]. Chordoma cells lacking PTEN pro-
tein expression indeed showed increased in vitro growth rate and shorter doubling time
compared with PTEN wild type chordoma cells. PTEN loss was associated with greater resis-
tance to PDGFR inhibition on invasion-migration assay in comparison to PTEN wild type
chordoma. Such observations are intriguing because chordomas are not rapidly growing
tumors and clinical progression frequently involves slow but insidious invasion into surround-
ing structures. Another potentially important clinical consideration resulting from PTEN defi-
ciency concerns genetic instability. Loss of PTEN has been linked to genetic instability of
cancers through a mechanism of CHK1 phosphorylation from unopposed activation of AKT
[40]. This leads to accumulation of DNA double-strand breaks due to cytoplasmic
Fig 4. Hypoxic expansion of Chordoma cells is mediated by stabilization of HIF-1α. (A) A representative cell proliferation assay assessed by the MTS
method for the UCH1 cell line (PTEN +/-) demonstrating increased proliferation with exposure to hypoxia (2% Oxygen) compared to normoxia (21%Oxygen).
This is representative of 3 independent experiments. *P<0.05, Two sample independent student’s t test. (B) A representative VEGF expression assay as
assessed by ELISA from cell culture supernatants for the UCH1 cell line (PTEN +/-) demonstrating increased expression of VEGF with exposure to hypoxia
compared with normoxic controls. This is representative of 3 independent experiments. *P<0.05, Two sample independent student’s t test. (C) A
representative immunoblot for HIF-1α demonstrating increased expression of HIF-1αwith hypoxia exposure compared with normoxia and abrogation of this
increase with administration of HDAC inhibitor.
doi:10.1371/journal.pone.0134426.g004
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Fig 5. Combined PDGFR and HDAC inhibition strikingly reduces proliferation and in vitro invasion of Chordoma cells. (A) Cell proliferation assay
assessed by MTSmethod using C18 (PTEN +/-) cells demonstrating significantly decreased proliferation in response to HDAC inhibition and combined
treatment with a PDGFR inhibitor compared to controls. This is representative of 3 independent of experiments. *P<0.05, Two sample independent student’s
t test. (B) Cell proliferation assays assessed by MTSmethod using UCH1 (PTEN +/-) and UCH2 (PTEN +/-) cells demonstrating significantly decreased
proliferation in response to HDAC inhibition and combined treatment with a PDGFR inhibitor compared to controls. This is representative of 3 independent of
experiments. *P<0.05, Two sample independent student’s t test. (C) Representative matrigel invasion assays with the C18 cell line (PTEN +/-) and UCH1 cell
line (PTEN +/-), respectively, demonstrating significant decrease in invasion in response to PDGFR inhibition, HDAC inhibition and PDGFR and HDAC
inhibition together. These images are representative of 3 independent experiments. *P<0.05, Two sample independent student’s t test compared to
untreated control. **P<0.05, Two sample independent student’s t test compared to PDGFR inhibitor alone.
doi:10.1371/journal.pone.0134426.g005
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sequestration of CHK1 [41]. In agreement with experimental findings, increased aneuploidy is
observed in human cancers with low PTEN expression [40, 42, 43]. It will be interesting to see
if chordomas with PTEN loss demonstrate greater genetic instability. Also, as expected from
inhibition of CHK1, PTEN deficient cells show impaired DNA repair checkpoint regulations
in response to ionizing radiation [40]. Because chordoma patients are often treated with exter-
nal beam radiation therapy after surgery, there is a theoretical risk for tumors that have PTEN
loss to accelerate genetic instability upon exposure to radiation.
To further investigate the functional significance of PTEN loss in chordomas, we restored
its expression in PTEN disrupted tumors using an adenoviral vector. Reintroduction of PTEN
was associated with reduction in proliferation and enhanced therapeutic sensitivity to PDGFR
inhibitor. However, in vivo reconstitution of PTEN is technically inefficient at this time. Due to
this technical limitation, we sought to identify another target that could act in concert with
PDGFR inhibition. Considering the consequences of PTEN loss, inhibitors of Akt and mTOR
were investigated serially in combination with PDGFR inhibitor. Neither combination was
compelling. mTOR inhibition merely resulted in reduction in the size of the chordoma cells
and had little effect on proliferation and invasion (Data not shown).
We chose to move forward with the combination of PDGFR and HDAC inhibition because:
1) HDAC inhibition has shown to attenuate cell migration, and chordomas for the most part
progress by local invasion; 2) Chordomas are characterized by regions of intratumoral hypoxia
and HDAC inhibition can down regulate expression of HIF-1α, a master regulator of the hyp-
oxic response [21]; 3) Receptor tyrosine kinase signaling pathway overlaps with hypoxic signal-
ing cascade and PTEN loss is associated with enhance HIF-1α expression [44]; 4) HDAC
inhibitor mediated cytotoxic mechanism is distinct from tyrosine kinase inhibition. We
observed that chordoma cells propagated at low oxygen tension had a proliferative advantage
and expressed both HIF-1α and its downstream target, VEGF. HDAC inhibition led to reduc-
tion in chordoma cell proliferation and invasion, and HIF-1α expression. A recent report
describing cytotoxic activity of HDAC inhibitors in chordoma further support our findings
[45]. The combination of PDGFR and HDAC inhibitors demonstrated striking reduction in
chordoma cell invasion, irrespective of PTEN status.
Our report illustrates the presence of therapeutically relevant genetic heterogeneity in chor-
doma. Intertumoral histologic heterogeneity is well recognized with descriptions of classic,
chondroid, and undifferentiated types. However, because most patients had skull base tumors,
it will be important to confirm our findings in sacral chordomas. This is particularly important
because the regional developmental pattern of notochord shows contributions from distinctive
cell types [46]. Nevertheless, within the chordomas of clival origin we found molecular hetero-
geneity that may have clinical relevance and allow for stratification of patients for therapy. The
observation that PTEN loss grants a greater resistance to PDGFR inhibition on migration-inva-
sion rather than growth was surprising but is consistent with the biological characteristics of
the disease. Characterization of tumors to identify key loss and gain of functions will not only
allow for selection of rational agents, but equally important is to define a more relevant end-
point to determine outcome. Future clinical studies of imatinib in chordoma may benefit from
a PTEN subgroup analysis to determine rate of progression with less emphasis on response.
Finally, our findings provide compelling preclinical rationale for a biomarker-driven clinical
study of combined inhibition of PDGFR and HDAC in chordomas.
Supporting Information
S1 Fig. Characterization of Chordoma cells. (A) Hematoxylin and eosin staining of a surgical
specimen from our series demonstrating the typical physaliphorous morphology of
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chordomas. (B) Immunohistochemical staining for brachyury of a surgical specimen from our
series demonstrating nuclear staining consistent with tissue of notochord origin. (C) Bright
field image of chordoma cells cultured from a surgical specimen demonstrating a recapitulation
of the physaliphorous morphology. (D) Immunoblot for brachyury demonstrating strong
expression of brachyury among the primary chordoma cell lines compared to glioma cell lines
(negative controls). This blot is representative of three independent experiments.
(TIF)
S2 Fig. Loss of heterozygosity (LOH) of PTEN. (A) PCR-based microsatellite LOH analysis of
10q23 locus, region that contains PTEN, from a surgical chordoma specimen demonstrating a
single peak consistent with LOH at this site. (B)PCR demonstrates two distinct peaks indicat-
ing an intact 10q23 locus.
(TIF)
S3 Fig. PDGRFR signaling cascade in Chordoma cells. (A) Immunoblot for multiple mem-
bers of the PDGFR signaling pathway in C18 cells demonstrats activation of signaling within
minutes of administration of exogenous PDGF (50 ng/mL). (B) Immunoblot of phosphor-
PDGFR in C11, C16, C21 and C22 in respond to PDGF stimulation.
(TIF)
S4 Fig. Ki-67 index and PTEN status. This graph demonstrates significantly lower Ki-67 pro-
liferation index among PTEN intact tumors compared with tumors with LOH.
(TIF)
S5 Fig. PTEN and association with proliferation. Additional studies performed on PTEN
deficient C21 primary culture chordoma cell shows restoration of PTEN retards proliferation
and establishes synergy with PDGFR inhibition.
(TIF)
S6 Fig. Nuclear expression of brachyury. Immunoblot was performed on isolated nuclear
protein fraction to demonstrate nuclear localization of brachyury that further supports immu-
nohistochemical staining.
(TIF)
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